3 Reasons Why The Biopharma M&A Market Is Ready For Takeoff

M&A activity in the healthcare sector has been slow in 2023, but experts predict an influx of biopharma M&A deals in the second half of the year due to a looming patent cliff, low valuations, and a weak IPO market. Several large pharmaceutical companies are seeking late-stage assets to offset revenue decline from expiring patents. The low valuations of biotech companies make them attractive to buyers, and the slow IPO market further drives M&A activity. However, antitrust scrutiny from federal regulators could pose a potential challenge.

medcitynews.com

Relevant topic timeline:

8/3/2023

Will we see any IPOs happening this year at all?

Main topic: The optimistic outlook for the tech industry and potential for IPOs. Key points: 1. The discovery of room-temperature superconductors could have a significant impact on the economy, but experts are still skeptical. 2. The macroeconomic climate is improving, leading to relief in tech valuations. 3. The venture capital market is showing signs of recovery, with an increase in mega-rounds and a slowdown in tech layoffs. 4. If market conditions continue to improve, a new wave of IPOs could be on the horizon. 5. The Nasdaq's performance suggests that the software IPO window may be opening up. 6. However, the timing of when founders will be able to go public is uncertain, with predictions ranging from the second half of 2024 for SaaS IPOs.

8/30/2023

Medicare should negotiate with drugmakers. But not set prices

The newly implemented rules in America that allow Medicare to negotiate drug prices could have damaging effects on innovation in the pharmaceutical industry and may discourage investment in new medicines, leading to fewer treatments in the future. Instead of focusing solely on price controls for drugs, regulators should address the issues within the rest of the supply chain, such as opaque middlemen and hospital mergers, to effectively lower healthcare costs.

9/5/2023

Wall Street Breakfast Podcast: AI: 11% Of Healthcare Budgets

The budget for artificial intelligence and machine learning in the healthcare sector is expected to reach 10.5% in 2024, up from 5.5% in 2022, and could have transformational effects on the industry beyond drug discovery, according to Morgan Stanley. Private equity firm Thoma Bravo is also in talks to acquire NextGen Healthcare, while Nestle-partnered weight loss capsules have succeeded in a pivotal trial, boosting shares of Epitomee Medical.

9/8/2023

Morgan Stanley and JPMorgan Update Stock Picks: Gilead, Apple, Cloud Data Providers in Focus

Summary: Bank of America predicts that Gilead Sciences could experience a jump of nearly 30% as the biopharma sector rebounds.

9/11/2023

Pharma Market Boom Coming: TBRC Reports Reveal $3 Trillion Industry by 2030 Driven by Disease, Healthcare Advances

The pharmaceutical market is expected to grow significantly by 2030, reaching $3,206 billion, driven by advances in healthcare technologies, increasing healthcare expenditures, and the rise of chronic diseases. The Business Research Company offers comprehensive reports to assist pharmaceutical companies with informed decision-making and staying competitive in this dynamic sector.

9/20/2023

Merck Rises to Become 4th Most Valuable Pharma Brand But Faces Growth Challenge After Keytruda Patent Expires

This article mentions Merck (NYSE:MRK) as the stock being discussed. The author's recommendation for Merck is a BUY rating at its current price. The core thesis revolves around Merck's consistent performance, strong growth in revenue and earnings, the success of its drugs Keytruda and Lagevrio, the recent acquisition of Prometheus Biosciences, and the company's future growth potential. Key information and data include Merck's rise to the 4th position among the pharmaceutical industry's most valuable brands, its top-line and bottom-line growth, the impact of the Prometheus acquisition on its financials, the expected patent expiration of Keytruda in 2028, the company's dividend yield and growth rate, and its valuation compared to peers.

Topics

Posted 8/21/2023, 8:54:45 PM